Table 1 Correlation between LC3/ALDH1 coexpression and clinicopathological profiles

Age, median (range)

67 (38–85)

64 (37–85)

Sex

  Male

37 (68.5)

23 (59.0)

0.342

  Female

17 (31.5)

16 (41.0)

Tumor location

  Head

28 (51.9)

29 (74.4)

0.177

  Neck

5 (9.3)

2 (5.1)

  Body/tail

12 (22.2)

4 (10.3)

  Uncinate process

9 (16.7)

4 (10.3)

Tumor size

   < 3 cm

30 (55.6)

22 (56.4)

0.935

   ≥ 3 cm

24 (44.4)

17 (43.6)

Lymph nodes

  Negative

30 (55.6)

16 (41.0)

0.167

  Positive

24 (44.4)

23 (59.0)

Margin status

  R0

41 (75.9)

25 (64.1)

0.462

  R1

11 (20.4)

12 (30.8)

  R2

2 (3.7)

2 (5.1)

Tumor grade

  Poorly diff.

11 (20.4)

6 (15.4)

0.345

  Moderate diff.

25 (46.3)

24 (61.5)

  Well diff.

18 (33.3)

9 (23.1)

Stage

  I

10 (18.5)

1 (2.6)

0.097

  II

40 (74.1)

36 (92.3)

  III

3 (5.6)

1 (2.6)

  IV

1 (1.9)

1 (2.6)

CA19-9

   < 37U/ml

12 (22.2)

8 (20.5)

0.843

   ≥ 37U/ml

42 (77.8)

31 (79.5)

Adjuvant therapy

  Yes

26 (48.1)

11 (28.2)

0.053

  No

28 (51.9)

28 (71.8)

Diabetes mellitus

  Yes

18 (33.3)

11 (28.2)

0.598

  No

36 (66.7)

28 (71.8)

Survival

  Yes

35 (64.8)

12 (30.8)

0.001

  No

19 (35.2)

27 (69.2)

Recurrence

  Yes

26 (48.1)

35 (89.7)

0.000

  No

28 (51.9)

4 (10.3)